Scott Requadt's Insider Trades & SAST Disclosures
Scott Requadt's most recent trade in Essa Pharma Inc was a trade of 50,000 Options done . Disclosure was reported to the exchange on March 25, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Scott Requadt.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Essa Pharma Inc | Scott Requadt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2024 | 50,000 | 50,000 | - | - | Options | |
| Essa Pharma Inc | Requadt Scott | Director | Other type of transaction at price $ 0.00 per share. | 30 Oct 2023 | 17,502 | 42,502 (0%) | 0% | 0 | Common Shares | |
| Essa Pharma Inc | Scott Requadt | Director | Other type of transaction at price $ 0.00 per share. | 30 Oct 2023 | 12,500 | 30,002 (0%) | 0% | 0 | Common Shares | |
| Talaris Therapeutics Inc | Scott Requadt | Former Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.08 per share. | 03 Jul 2023 | 11,786 | 578,403 | - | 3.1 | 36,301 | Common Stock |
| Talaris Therapeutics Inc | Scott Requadt | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 320,000 | 320,000 | - | - | Stock Option (Right to Buy) | |
| Talaris Therapeutics Inc | Scott Requadt | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 320,000 | 320,000 | - | - | Stock Appreciation Right | |
| Talaris Therapeutics Inc | Scott Requadt | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.75 per share. | 01 Feb 2023 | 4 | 590,193 | - | 0.8 | 3 | Common Stock |
| Talaris Therapeutics Inc | Scott Requadt | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2022 | 80,000 | 590,189 | - | 0 | Common Stock | |
| Talaris Therapeutics Inc | Scott Requadt | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 4.25 per share. | 29 Jul 2022 | 39,382 | 508,680 | - | 4.3 | 167,374 | Common Stock |
| Talaris Therapeutics Inc | Scott Requadt | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 4.24 per share. | 26 Jul 2022 | 5,528 | 466,208 | - | 4.2 | 23,439 | Common Stock |
| Talaris Therapeutics Inc | Scott Requadt | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 4.25 per share. | 26 Jul 2022 | 3,090 | 469,298 | - | 4.3 | 13,133 | Common Stock |
| Talaris Therapeutics Inc | Scott Requadt | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 3.75 per share. | 22 Jul 2022 | 9,444 | 460,680 | - | 3.7 | 35,412 | Common Stock |
| Essa Pharma Inc | Scott Requadt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2022 | 22,500 | 22,500 | - | - | Stock Option (Right to Buy) | |
| Talaris Therapeutics Inc | Scott Requadt | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| Talaris Therapeutics Inc | Scott Requadt | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 13.00 per share. | 01 Feb 2022 | 1,470 | 451,236 | - | 13 | 19,110 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges